Immunome IMNM
NASDAQ IMNM
$21.89 +0.21 (+0.97%)
At close: Sep 29, 2026 · 4:00 PM EDT

Immunome (IMNM) EBITDA Margin (2023 - 2025)

Updated

Immunome (IMNM) posted EBITDA Margin of -3192.81% for FY2025, up 171.86 percentage points from -3364.67% in FY2024.

Analysis

Immunome (IMNM) EBITDA Margin (2023 - 2025) Analysis & Trends

  • Business Quant data shows IMNM's EBITDA Margin at -3364.67% in FY2024 (-2586.89 pp) and -777.79% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Immunome 2.46 Bn 429.67 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,141.74%
Mar 31, 2025 -1,504.61%
Dec 31, 2024 -3,012.67%
Sep 30, 2024 -1,722.03%
Jun 30, 2024 -1,669.20%
Mar 31, 2024 -12,841.79%
Dec 31, 2023 -2,468.87%
Sep 30, 2023 -126.84%
Jun 30, 2023 -133.05%
Mar 31, 2023 -185.15%
API Access

Immunome EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IMNM&period=max&api_key=YOUR_API_KEY